Studienliteratur zum Neuroblastom

Studienliteratur Neuroblastome

 Suche nach Artikeln in den letzten sechs Monaten in PubMed (externes Informationsangebot)
  1. Thole TM, Toedling J, Sprüssel A, Pfeil S, Savelyeva L, Capper D, Messerschmidt C, Beule D, Groeneveld-Krentz S, Eckert C, Gambara G, Henssen AG, Finkler S, Schulte JH, Sieber A, Bluethgen N, Regenbrecht CRA, Künkele A, Lodrini M, Eggert A, Deubzer HE: Reflection of neuroblastoma intratumor heterogeneity in the new OHC-NB1 disease model. International journal of cancer 2019 Jul 15; [PMID: 31304977]
  2. Kreitz K, Ernst A, Schmidt R, Simon T, Fischer M, Volland R, Hero B, Berthold F: A new risk score for patients after first recurrence of stage 4 neuroblastoma aged ≥18 months at first diagnosis. Cancer medicine 2019 Oct 20; [PMID: 31631570]
  3. Berthold F, Ernst A, Hero B, Klingebiel T, Kremens B, Schilling FH, Simon T: Correction: Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation. British journal of cancer 2019 Sep 24; [PMID: 31551583]
  4. Berthold F: From a single meeting to a scientific community: Quantification of the . Pediatric blood & cancer 2019, 66:e27696 [PMID: 30848089]
  5. Ackermann S, Cartolano M, Hero B, Welte A, Kahlert Y, Roderwieser A, Bartenhagen C, Walter E, Gecht J, Kerschke L, Volland R, Menon R, Heuckmann JM, Gartlgruber M, Hartlieb S, Henrich KO, Okonechnikov K, Altmüller J, Nürnberg P, Lefever S, de Wilde B, Sand F, Ikram F, Rosswog C, Fischer J, Theissen J, Hertwig F, Singhi AD, Simon T, Vogel W, Perner S, Krug B, Schmidt M, Rahmann S, Achter V, Lang U, Vokuhl C, Ortmann M, Büttner R, Eggert A, Speleman F, O'Sullivan RJ, Thomas RK, Berthold F, Vandesompele J, Schramm A, Westermann F, Schulte JH, Peifer M, Fischer M: A mechanistic classification of clinical phenotypes in neuroblastoma. Science (New York, N.Y.) 2018 Dec 7; 362: 1165 [PMID: 30523111]
  6. Dübbers M, Simon T, Berthold F, Fischer J, Volland R, Hero B, Cernaianu G: Retrospective analysis of relapsed abdominal high-risk neuroblastoma. Journal of pediatric surgery 2018, 53: 558 [PMID: 29021103]
  7. Berthold F, Ernst A, Hero B, Klingebiel T, Kremens B, Schilling FH, Simon T: Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation. British journal of cancer 2018, 119: 282 [PMID: 29991700]
  8. Berthold F, Spix C, Kaatsch P, Lampert F: Incidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979-2015. Paediatric drugs 2017, 19: 577 [PMID: 28786082]
  9. Ladenstein R, Pötschger U, Pearson ADJ, Brock P, Luksch R, Castel V, Yaniv I, Papadakis V, Laureys G, Malis J, Balwierz W, Ruud E, Kogner P, Schroeder H, de Lacerda AF, Beck-Popovic M, Bician P, Garami M, Trahair T, Canete A, Ambros PF, Holmes K, Gaze M, Schreier G, Garaventa A, Vassal G, Michon J, Valteau-Couanet D, SIOP Europe Neuroblastoma Group (SIOPEN): Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. The Lancet. Oncology 2017, 18: 500 [PMID: 28259608]
  10. Fischer J, Pohl A, Volland R, Hero B, Dübbers M, Cernaianu G, Berthold F, von Schweinitz D, Simon T: Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months. BMC cancer 2017 Aug 4; 17: 520 [PMID: 28778185]
  11. Berthold F, Hömberg M, Proleskovskaya I, Mazanek P, Belogurova M, Ernst A, Sterba J: Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma. Pediatric hematology and oncology 2017, 34: 308 [PMID: 29148865]
  12. Hero B, Clement N, Øra I, Pierron G, Lapouble E, Theissen J, Pasqualini C, Valteau-Couanet D, Plantaz D, Michon J, Delattre O, Tardieu M, Schleiermacher G: Genomic Profiles of Neuroblastoma Associated With Opsoclonus Myoclonus Syndrome. Journal of pediatric hematology/oncology 2018, 40: 93 [PMID: 29135842]
  13. Moreno L, Caron H, Geoerger B, Eggert A, Schleiermacher G, Brock P, Valteau-Couanet D, Chesler L, Schulte JH, De Preter K, Molenaar J, Schramm A, Eilers M, Van Maerken T, Johnsen JI, Garrett M, George SL, Tweddle DA, Kogner P, Berthold F, Koster J, Barone G, Tucker ER, Marshall L, Herold R, Sterba J, Norga K, Vassal G, Pearson AD: Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Expert opinion on drug discovery 2017, 12: 801 [PMID: 28604107]
  14. Simon T, Hero B, Schulte JH, Deubzer H, Hundsdoerfer P, von Schweinitz D, Fuchs J, Schmidt M, Prasad V, Krug B, Timmermann B, Leuschner I, Fischer M, Langer T, Astrahantseff K, Berthold F, Lode H, Eggert A: 2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors. Klinische Padiatrie 2017, 229: 147 [PMID: 28561228]
  15. Schmidt M, Hero B, Simon T: I-131-mIBG therapy in neuroblastoma: established role and prospective applications. Clinical and Translational Imaging 2016, Volume 4, Issue 2, 87 [DOI: 10.1007/s40336-016-0173-z]
  16. Morgenstern DA, London WB, Stephens D, Volchenboum SL, Simon T, Nakagawara A, Shimada H, Schleiermacher G, Matthay KK, Cohn SL, Pearson AD, Irwin MS: Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. European journal of cancer (Oxford, England : 1990) 2016, 65: 1 [PMID: 27434878]
  17. Meany HJ, London WB, Ambros PF, Matthay KK, Monclair T, Simon T, Garaventa A, Berthold F, Nakagawara A, Cohn SL, Pearson AD, Park JR: Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project. Pediatric blood & cancer 2014, [PMID: 25044743]
  18. Simon T, Häberle B, Hero B, von Schweinitz D, Berthold F: Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013, 31: 752 [PMID: 23284039]
  19. Simon T, Niemann CA, Hero B, Henze G, Suttorp M, Schilling FH, Berthold F: Short- and long-term outcome of patients with symptoms of spinal cord compression by neuroblastoma. Developmental medicine and child neurology 2012, 54: 347 [PMID: 22329756]
  20. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Klingebiel T, Berthold F: Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14. 18 or oral metronomic chemotherapy. BMC Cancer 2011, 18; 11: 21. [PMID: 21244693]
  21. Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B: Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer 2011, 56: 578 [PMID: 21298742]
  22. Sudbrock F, Schmidt M, Simon T, Eschner W, Berthold F, Schicha H: Dosimetry for (131)I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma. European journal of nuclear medicine and molecular imaging 2010, [PMID: 20179922]
  23. Fischer M, Bauer T, Oberthür A, Hero B, Theissen J, Ehrich M, Spitz R, Eils R, Westermann F, Brors B, König R, Berthold F: Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q. Oncogene 2010, 29: 865 [PMID: 19901960]
  24. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD, INRG Task Force: The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. Journal of clinical oncology 2009, 27: 298 [PMID: 19047290]
  25. Theissen J, Boensch M, Spitz R, Betts D, Stegmaier S, Christiansen H, Niggli F, Schilling F, Schwab M, Simon T, Westermann F, Berthold F, Hero B: Heterogeneity of the MYCN oncogene in neuroblastoma. Clinical cancer research 2009, 15: 2085 [PMID: 19276282]
  26. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK, INRG Task Force: The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. Journal of clinical oncology 2009, 27: 289 [PMID: 19047291]
  27. Benz-Bohm G, Hero B, Gossmann A, Simon T, Körber F, Berthold F: Focal nodular hyperplasia of the liver in longterm survivors of neuroblastoma How much diagnostic imaging is necessary? European journal of radiology 2009, [PMID: 19369017]
  28. Oberthuer A, Theissen J, Westermann F, Hero B, Fischer M: Molecular characterization and classification of neuroblastoma. Future oncology (London, England) 2009, 5: 625 [PMID: 19519203]
  29. Hoene V, Fischer M, Ivanova A, Wallach T, Berthold F, Dame C: GATA factors in human neuroblastoma: distinctive expression patterns in clinical subtypes. British journal of cancer 2009, 101: 1481 [PMID: 19707195]
  30. Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Yalcin B, Dee R, van Noesel MM, Berthold F, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA: Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers. Clinical chemistry 2009, 55: 1316 [PMID: 19460840]
  31. Voth H, Oberthuer A, Simon T, Kahlert Y, Berthold F, Fischer M: Co-regulated expression of HAND2 and DEIN by a bidirectional promoter with asymmetrical activity in neuroblastoma. BMC molecular biology 2009, 10: 28 [PMID: 19348682]
  32. Schmidt M, Simon T, Hero B, Schicha H, Berthold F: The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. European journal of cancer (Oxford, England : 1990) 2008, 44: 1552 [PMID: 18424129]
  33. Fischer M, Spitz R, Oberthür A, Westermann F, Berthold F: Risk estimation of neuroblastoma patients using molecular markers. Klinische Padiatrie 2008, 220: 137 [PMID: 18478485]
  34. Bénard J, Raguénez G, Kauffmann A, Valent A, Ripoche H, Joulin V, Job B, Danglot G, Cantais S, Robert T, Terrier-Lacombe MJ, Chassevent A, Koscielny S, Fischer M, Berthold F, Lipinski M, Tursz T, Dessen P, Lazar V, Valteau-Couanet D: MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S. Molecular oncology 2008, 2: 261 [PMID: 19383347]
  35. Oberthuer A, Kaderali L, Kahlert Y, Hero B, Westermann F, Berthold F, Brors B, Eils R, Fischer M: Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR. Clinical cancer research : an official journal of the American Association for Cancer Research 2008, 14: 6590 [PMID: 18927300]
  36. Hero B, Simon T, Spitz R, Ernestus K, Gnekow AK, Scheel-Walter HG, Schwabe D, Schilling FH, Benz-Bohm G, Berthold F: Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. Journal of clinical oncology 2008, 26: 1504 [PMID: 18349403]
  37. Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Kleijn I, Dee R, Hooft L, van Noesel MM, Bierings M, Berthold F, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA: PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. Journal of clinical oncology 2008, 26: 5443 [PMID: 18838715]
  38. Westermann F, Muth D, Benner A, Bauer T, Henrich KO, Oberthuer A, Brors B, Beissbarth T, Vandesompele J, Pattyn F, Hero B, König R, Fischer M, Schwab M: Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome biology 2008, 9:R150 [PMID: 18851746]
  39. Simon T, Längler A, Berthold F, Klingebiel T, Hero B: Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial. Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology 2007, 29: 101 [PMID: 17279006]
  40. Voth H, Oberthuer A, Simon T, Kahlert Y, Berthold F, Fischer M: Identification of DEIN, a novel gene with high expression levels in stage IVS neuroblastoma. Molecular cancer research : MCR 2007, 5: 1276 [PMID: 18171985]
  41. Schmidt M, Simon T, Hero B, Eschner W, Dietlein M, Sudbrock F, Bongartz R, Berthold F, Schicha H: Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nuklearmedizin. Nuclear medicine 2006, 45: 145-51; quiz N39 [PMID: 16964339]
  42. Spitz R, Oberthuer A, Zapatka M, Brors B, Hero B, Ernestus K, Oestreich J, Fischer M, Simon T, Berthold F: Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes, chromosomes & cancer 2006, 45: 1130 [PMID: 16958102]
  43. Oberthuer A, Warnat P, Kahlert Y, Westermann F, Spitz R, Brors B, Hero B, Eils R, Schwab M, Berthold F, Fischer M: Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease. Cancer letters 2007, 250: 250 [PMID: 17126996]
  44. Spitz R, Hero B, Simon T, Berthold F: Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clinical cancer research 2006, 12(11 Pt 1): 3368 [PMID: 16740759]
  45. Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, Ernestus K, König R, Haas S, Eils R, Schwab M, Brors B, Westermann F, Fischer M: Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006, 24: 5070 [PMID: 17075126]
  46. Fischer M, Oberthuer A, Brors B, Kahlert Y, Skowron M, Voth H, Warnat P, Ernestus K, Hero B, Berthold F: Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome. Clinical cancer research : an official journal of the American Association for Cancer Research 2006, 12: 5118 [PMID: 16951229]
  47. Simon T, Hero B, Bongartz R, Schmidt M, Müller RP, Berthold F: Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease. Strahlentherapie und Onkologie 2006, 182: 389 [PMID: 16826357]
  48. Schumacher-Kuckelkorn R, Hero B, Ernestus K, Berthold F: Lacking immunocytological GD2 expression in neuroblastoma: report of 3 cases. Pediatric blood & cancer 2005, 45: 195 [PMID: 15800908]
  49. Fischer M, Skowron M, Berthold F: Reliable transcript quantification by real-time reverse transcriptase-polymerase chain reaction in primary neuroblastoma using normalization to averaged expression levels of the control genes HPRT1 and SDHA. The Journal of molecular diagnostics 2005, 7: 89 [PMID: 15681479]
  50. Wolfl M, Jungbluth AA, Garrido F, Cabrera T, Meyen-Southard S, Spitz R, Ernestus K, Berthold F: Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer immunology, immunotherapy : CII 2005, 54: 400 [PMID: 15449039]
  51. Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, Klingebiel T, Kremens B, Schilling FH, Schrappe M, Simon T, Hero B: Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. The lancet oncology 2005, 6: 649 [PMID: 16129365]
  52. Eich HT, Muller RP, Micke O, Kocher M, Berthold F, Hero B: Esthesioneuroblastoma in childhood and adolescence. Better prognosis with multimodal treatment? Strahlentherapie und Onkologie 2005, 181: 378 [PMID: 15925980]
  53. Boensch M, Oberthuer A, Fischer M, Skowron M, Oestreich J, Berthold F, Spitz R: Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q. Diagnostic molecular pathology 2005, 14: 177 [PMID: 16106200]
  54. Simon A, Beutel K, Marklein G, Fleischhack G: Bacterial infections in pediatric cancer patients. Klin Pädiatr 2005, 217 Suppl 1:S17 [PMID: 16288351]
  55. Hero B, Berthold F: Neuroblastoma. In: D. Reinhard (Hrsg.), Leitlinien Kinderheilkunde und Jugendmedizin Urban & Fischer, 2005, L5 1 [ISBN: 3-437-21867-0
  56. Claviez A, Lakomek M, Ritter J, Suttorp M, Kremens B, Dickerhoff R, Harms D, Berthold F, Hero B: Low occurrence of familial neuroblastomas and ganglioneuromas in five consecutive GPOH neuroblastoma treatment studies. European journal of cancer (Oxford, England : 1990) 2004, 40: 2760 [PMID: 15648116]
  57. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D, Berthold F: Consolidation treatment with chimeric anti-GD2-antibody ch14. 18 in children older than 1 year with metastatic neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004, 22: 3549 [PMID: 15337804]
  58. Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG, Chen QR, Whiteford CC, Bilke S, Krasnoselsky AL, Cenacchi N, Catchpoole D, Berthold F, Schwab M, Khan J: Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer research 2004, 64: 6883 [PMID: 15466177]
  59. Spitz R, Hero B, Skowron M, Ernestus K, Berthold F: MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification. European journal of cancer (Oxford, England : 1990) 2004, 40: 2753 [PMID: 15571958]
  60. Jensen M, Tawadros S, Sedlacek HH, Schultze JL, Berthold F: NK cell depletion diminish tumour-specific B cell responses. Immunology letters 2004, 93(2-3): 205 [PMID: 15158618]
  61. Schilling FH, Spix C, Berthold F, Erttmann R, Sander J, Treuner J, Michaelis J: Children may not benefit from neuroblastoma screening at 1 year of age. Updated results of the population based controlled trial in Germany. Cancer letters 2003, 197(1-2): 19 [PMID: 12880955]
  62. Spitz R, Hero B, Ernestus K, Berthold F: Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2003, 9: 4835 [PMID: 14581355]
  63. Krams M, Heidebrecht HJ, Hero B, Berthold F, Harms D, Parwaresch R, Rudolph P: Repp86 expression and outcome in patients with neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003, 21: 1810 [PMID: 12721258]
  64. Berthold F, Hero B, Kremens B, Handgretinger R, Henze G, Schilling FH, Schrappe M, Simon T, Spix C: Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer letters 2003, 197(1-2): 11 [PMID: 12880954]
  65. Simon T, Hero B, Hunneman DH, Berthold F: Tumour markers are poor predictors for relapse or progression in neuroblastoma. European journal of cancer (Oxford, England : 1990) 2003, 39: 1899 [PMID: 12932669]
  66. Jensen M, Ernestus K, Kemshead J, Klehr M, Von Bergwelt-Baildon MS, Schinkothe T, Schultze JL, Berthold F: The bi-specific CD3 x NCAM antibody: a model to preactivate T cells prior to tumour cell lysis. Clinical and experimental immunology 2003, 134: 253 [PMID: 14616785]